Clinical trials: Attention
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Mood
Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure
The purpose of this study was to measure potential mood, cognition and blood pressure effects of theobromine and caffeine in healthy women
- Trial name
- NCT01288547
- Testing
- theobromine, Caffeine, caffeine + theobromine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
End Stage Renal Disease
Carry Life@ UF System Clinical Study
The Carry Life UF system performs peritoneal ultrafiltration by adding glucose to the low glucose strength (1.36%) peritoneal dialysis fluid which has been instilled into the peritoneal cavity prior to the connection of the…
- Trial name
- NCT05874804
- Testing
- Carry Life UF, 2.27% glucose peritoneal dialysis dwell
- Where
- 11 sites in Italy, Sweden and 1 more
- Volunteers
- 28 people
- Sponsor
- Triomed AB
ADHD, Autism
Acceptability, Feasibility, and Development of an AI Driven, Multi-sensor, Non-invasive Digital Mental Health Platform in Children With ADHD and Emotional Symptoms
This is an observational study collecting data using a wearable to measure the biometric features in youth with Attention deficit hyperactivity disorder(ADHD) and Autism.
- Trial name
- NCT06311370
- Testing
- Observation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MaxisHealth
Healthy Subjects
Measurement of HTL0016878 in Cerebrospinal Fluid
A Phase 1, open-label, randomised, single oral dose study to determine the concentration of HTL0016878 in CSF and plasma in healthy male subjects following dosing with HTL0016878 10 mg or 20 mg oral solution
- Trial name
- NCT04849286
- Testing
- HTL0016878
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Attention-Deficit/Hyperactivity Disorder
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from…
- Trial name
- NCT00997984
- Testing
- extended-release guanfacine hydrochloride (SPD503), extended-release guanfacine hydrochloride
- Where
- 46 sites in United States, Canada
- Volunteers
- 340 people
- Sponsor
- Shire
ADHD
Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD.
- Trial name
- NCT01124708
- Testing
- TC-5619-238
- Where
- 16 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire
ADHD
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom setting based on the Permanent Product Measure…
- Trial name
- NCT01274221
- Testing
- SPD489
- Where
- 6 sites in United States
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
- Trial name
- NCT00443391
- Testing
- ABT-089
- Where
- 21 sites in United States
- Volunteers
- 141 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention Deficit Hyperactivity Disorder
Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the change in neuropsychological status from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with ADHD.
- Trial name
- NCT00216918
- Testing
- Atomoxetine Hydrochloride
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Neovascular Age-related Macular Degeneration
Safety and Efficacy of AM712 in Patients with NAMD
The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with…
- Trial name
- NCT05345769
- Testing
- AM712(ASKG712)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- AffaMed Therapeutics Limited
Maximum Observed Plasma Glucose Concentration (Cmax)
Processed Orange and the Glycemic Response
Randomized, placebo controlled, double blind, postprandial crossover study in male subjects. 3 intervention arms, consisting of a control (Product A), a low dose processed whole orange (Product B) and a high dose processed whole…
- Trial name
- POGR (NCT02112851)
- Testing
- Orange flavored beverage
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Attention Deficit Hyperactivity Disorder (ADHD)
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
Assess the efficacy \& tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.
- Trial name
- NCT00500071
- Testing
- Vyvanse (lisdexamfetamine dimesylate)
- Where
- 46 sites in United States
- Volunteers
- 318 people
- Sponsor
- Shire
ADHD
A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD
This pilot study is a randomized, double-blind, sham-controlled study designed to evaluate the efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in college students with ADHD. A total of 40 subjects will be treated.
- Trial name
- MeRT-USC-009 (NCT03066505)
- Testing
- Active MeRT Treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Wave Neuroscience
Anxiety, Depression, Anxiety
Study to Identify if OVR Health's VR-Kit is Safe to Use and Helps to Improve Focus, Attention and Reduce Worry & Rumination.
This is a randomized-controlled interventional treatment study with three arms of comparable demographics to evaluate the safety and efficacy of OVR Health's VR experience to improve control over the focus of attention and reduce…
- Trial name
- NCT05291429
- Testing
- OVR Health's VR experience
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Oxford VR
Healthy, Plasma Concentration of YM060
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake
A study to compare time-course changes of plasma concentration of YM060 orally-disintegrating tablet with those of conventional tablet. Tablets will be administered with water.
- Trial name
- NCT01394653
- Testing
- YM060
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Adult Attention-deficit Hyperactivity Disorder (ADHD)
A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
The purpose of this study is to investigate the safety, tolerance, food effect, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of extended release (XR) formulations of Centanafadine (CTN) in Young…
- Trial name
- NCT02827513
- Testing
- CTN SR1, CTN XR1, CTN XR2
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.